全髋关节置换术后分次静脉地塞米松方案是否优于单次高剂量?一项随机盲法安慰剂对照试验
该随机盲法安慰剂对照试验纳入165例全髋关节置换术患者,比较安慰剂、单次术前20mg地塞米松和两次10mg地塞米松方案。结果显示地塞米松可短期减轻疼痛、恶心呕吐和炎症并改善活动度,分次方案在术后第2、3天动态疼痛、炎症指标、活动度和满意度上优于单次高剂量。
要点
- 围术期地塞米松可短期减轻全髋置换术后疼痛、PONV和炎症,改善活动度。
- 分次10mg方案在术后第2、3天动态疼痛和炎症指标上优于单次20mg。
- 分次方案在术后第3天活动度和满意度上优于单次高剂量。
核心结论
- 围术期地塞米松在全髋关节置换术后早期提供减轻疼痛、PONV和炎症及增加活动度的短期优势。
- 分次给药方案在减轻疼痛和炎症、增加活动度方面优于单次高剂量,患者满意度更高。
研究设计与样本
- 随机盲法安慰剂对照试验,165例患者随机分为三组:A组安慰剂、B组单次术前20mg地塞米松、C组两次10mg地塞米松。
- 患者、外科医生和收集结局数据的工作人员对分组设盲。
主要发现
- 术后第1、2天,B组和C组静息疼痛评分显著低于A组。
- 术后第1、2、3天,B组和C组动态疼痛评分及CRP、IL-6水平显著低于A组。
- B组和C组较A组PONV发生率更低、镇痛和止吐补救用药更少、ROM改善、LOS缩短、满意度更高。
- C组术后第2、3天动态疼痛评分及IL-6、CRP水平显著低于B组,术后第3天ROM和满意度高于B组。
- 任何组均未发生SSI或GIB。
关键数值与推荐
- 主要结局为术后静息和活动时十点数字评定量表(NRS)疼痛水平。
- B组和C组术后第1、2天静息疼痛评分显著低于A组。
- C组术后第2、3天动态疼痛评分及IL-6、CRP水平显著低于B组。
- C组术后第3天ROM和满意度高于B组。
临床怎么用
- 全髋关节置换围术期可考虑使用地塞米松以短期减轻疼痛、PONV和炎症并改善活动度。
- 分次10mg方案可能较单次20mg方案在术后第2、3天提供更好的疼痛和炎症控制及满意度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Intravenous dexamethasone has been shown to reduce immediate postoperative pain after total hip arthroplasty (THA), though the effects are short-lived. We aimed to assess whether two equivalent perioperative split doses were more effective than a single preoperative dose. METHODS: A total of 165 patients were randomly assigned into three groups: two perioperative saline injections (Group A, placebo), a single preoperative dose of 20 mg dexamethasone and a postoperative saline injection (Group B), and two perioperative doses of 10 mg dexamethasone (Group C). Patients, surgeons, and staff collecting outcome data were blinded to allocation. The primary outcome was postoperative pain level reported on a ten-point Numerical Rating Scale (NRS) at rest and during activity. The use of analgesic and antiemetic rescue, incidence of postoperative nausea and vomiting (PONV), CRP and interleukin-6 (IL-6) levels, range of motion (ROM), length of stay (LOS), patient satisfaction, and the incidence of surgical site infection (SSI) and gastrointestinal bleeding (GIB) in the three months postoperatively, were also compared. RESULTS: The pain scores at rest were significantly lower in Groups B and C than in Group A on postoperative days 1 and 2. The dynamic pain scores and CRP and IL-6 levels were significantly lower for Groups B and C compared to Group A on postoperative days 1, 2, and 3. Patients in Groups B and C had a lower incidence of PONV, reduced use of analgesic and antiemetic rescue, improved ROM, shorter LOS, and reported higher satisfaction than in Group A. Patients in Group C had significantly lower dynamic pain scores and IL-6 and CRP levels on postoperative days 2 and 3, and higher ROM and satisfaction on postoperative day 3 than in Group B. No SSI or GIB occurred in any group. CONCLUSION: Perioperative dexamethasone provides short-term advantages in reducing pain, PONV, and inflammation, and increasing range of motion in the early postoperative period after THA. A split-dose regimen was superior to a single high dose in reducing pain and inflammation, and increasing ROM, with better patient satisfaction. Level of evidence: I Cite this article: Bone Joint J 2020;102-B(11):1497-1504.
引用
- Lei Y, Huang Z, Huang Q, et al. Is a split-dose intravenous dexamethasone regimen superior to a single high dose in reducing pain and improving function after total hip arthroplasty? A randomized blinded placebo-controlled trial. Bone Joint J. 2020. PMID: 33135436. doi:10.1302/0301-620X.102B11.BJJ-2020-1078.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。